Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.08
- Piotroski Score 5.00
- Grade Hold
- Symbol (ORTX)
- Company Orchard Therapeutics plc
- Price $16.70
- Changes Percentage (0.3%)
- Change $0.05
- Day Low $16.64
- Day High $16.72
- Year High $16.72
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.10
- Trailing P/E Ratio -4.0731707317073
- Forward P/E Ratio -4.0731707317073
- P/E Growth -4.0731707317073
- Net Income $-7,883,000
Income Statement
Quarterly
Annual
Latest News of ORTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
XRTX Stock Price | XORTX Therapeutics Inc. Stock Quote (U.S.: Nasdaq) | MarketWatch
XORTX Therapeutics, Inc. is a biopharmaceutical company based in Calgary, Canada, focusing on developing innovative therapies for rare diseases like polycystic kidney disease and conditions related to...
By MarketWatch | 4 weeks ago -
XORTX Therapeutics Gain 87% Following Publication of Research Supporting Treatment Pipeline
XORTX Therapeutics' stock surged 87% to $2.15 after recent research on genetic regulation of xanthine oxidase supporting their treatment approach for kidney and other diseases. The company plans to pr...
By MarketWatch | 1 month ago
